A case of refractory dermatomyositis responsive to tofacitinib

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 4, 2017, Pages e19-

  Paik, Julie J ^a   Christopher Stine, Lisa ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; TOFACITINIB; IMMUNOSUPPRESSIVE AGENT; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTHRITIS; CASE REPORT; DERMATOMYOSITIS; DRUG EFFICACY; DRUG SAFETY; DYNAMOMETRY; FEMALE; HUMAN; LETTER; MIDDLE AGED; MUSCLE WEAKNESS; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; RASH; REFRACTORY DERMATOMYOSITIS; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; RETREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

AZATHIOPRINE; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MIDDLE AGED; MYCOPHENOLIC ACID; PIPERIDINES; PYRIMIDINES; PYRROLES; RETREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84994792213     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.08.009     Document Type: Letter

References (3)

1. [1] Rosengren, S., Corr, M., Firestein, G.S., Boyle, D.L., The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 71 (2012), 440–447.
2. [2] Hornung, T., Janzen, V., Heidgen, F.-J., Wolf, D., Bieber, T., Wenzel, J., Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 371 (2014), 2537–2538.
3. [3] Kurtzman, D.J.B., Wright, N.A., Lin, J., Femia, A.N., Merola, J.F., Patel, M., et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol 152 (2016), 944–945.